Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02099058 (Clinical Trial/ ABBV-399)

Study Title
A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors (NCT02099058)

Trial Description
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 in subjects with advanced solid tumors.

This trial is sponsored by AbbVie®.

Study Data

  • Condition: 
    • Advanced Solid Tumor Cancer
  • Interventions:
    • Drugs used in this trial
      • ABBV-399
      • Erlotinib
      • Cetuximab
      • Bevacizumab
      • Nivolumab
  • Phase: I
  • Estimated Enrollment: 146
  • Start: April 2014
  • Estimated Completion: April 2017
  • Last updated: April 2016
  • Last verified: April 2016

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: April 16, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar